Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Active not recruiting 2Available 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 3Observational 1Expanded_access 1

Sponsor

Cancer Type

Lymphoid 5Other hematologic neoplasm 2

Conditions

Burkitt Lymphoma 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Lymphoma 1Leukemia 1

Interventions

Specimen Handling 642pembrolizumab 565Magnetic Resonance Spectroscopy 548Carboplatin 426Cisplatin 377Cyclophosphamide 374Biopsy 365Paclitaxel 306Nivolumab 303Gemcitabine 303Radiotherapy 274Bevacizumab 240Dexamethasone 209fludarabine 207Docetaxel 191durvalumab 183atezolizumab 177Oxaliplatin 174venetoclax 168Fluorouracil 167Rituximab 166Pemetrexed 164Capecitabine 161Radiation 159Doxorubicin 159Radiosurgery 150Etoposide 137Ipilimumab 135Leucovorin 133Lenalidomide 132

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
tisagenlecleucel × 90 days × Clear all
NCT03876769 2026-06-02

CASSIOPEIA

Novartis

Phase 2 Active not recruiting
121 enrolled
Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

NCT06785818 2026-05-05

Long-term Follow up Local Registry Study of Kymriah in South Korea

Novartis

Recruiting
500 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT03601442 2026-04-23

Managed Access Programs for CTL019, Tisagenlecleucel

Novartis

Available
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT04094311 2026-04-20

Study of Out of Specification for Tisagenlecleucel

Novartis

Phase 3 Recruiting
200 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05888493 2026-04-17

LEDA

Novartis

Phase 3 Active not recruiting
109 enrolled
Lymphoid

Lymphoma, Follicular, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡